Last 48 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.33 | 18.00 | 17.96 | 23.93 | 21.61 | 16.27 | 9.90 | 33.89 | 108.83 | 47.07 | 74.45 | — | 121.11 | 1426.72 | 26.11 | 29.50 | 37.89 | 31.69 | 26.48 | 49.85 | 128.93 |
| — | +10.7% | +81.3% | -29.4% | -80.1% | -65.4% | -86.7% | — | -10.1% | -96.7% | +185.1% | — | +219.6% | +4402.7% | -1.4% | -40.8% | -70.6% | -25.6% | -45.4% | +42.3% | +311.2% | |
| P/S Ratio | 3.05 | 3.33 | 3.46 | 3.92 | 3.62 | 2.52 | 2.70 | 4.28 | 4.40 | 3.95 | 3.72 | 2.99 | 3.00 | 3.73 | 5.20 | 5.23 | 6.91 | 5.94 | 5.48 | 8.33 | 7.52 |
| — | +32.3% | +27.9% | -8.4% | -17.5% | -36.1% | -27.5% | +42.9% | +46.3% | +5.8% | -28.3% | -42.8% | -56.5% | -37.3% | -5.1% | -37.2% | -8.1% | -31.7% | -31.5% | +19.9% | +6.2% | |
| P/B Ratio | 2.13 | 2.12 | 2.29 | 2.52 | 2.62 | 1.76 | 1.88 | 2.50 | 2.77 | 2.43 | 2.36 | 1.85 | 1.85 | 1.37 | 3.05 | 3.02 | 4.11 | 3.42 | 3.40 | 4.30 | 4.32 |
| — | +20.5% | +22.1% | +0.5% | -5.3% | -27.4% | -20.5% | +35.2% | +49.3% | +77.6% | -22.7% | -38.8% | -54.9% | -60.1% | -10.2% | -29.7% | -4.8% | -26.4% | -30.5% | +6.4% | -1.6% | |
| P/FCF | 12.67 | 11.33 | 15.46 | 18.29 | 15.57 | 8.86 | 76.57 | 18.78 | 14.95 | 15.27 | 88.64 | 76.21 | 22.64 | 49.41 | 88.29 | 38.77 | 41.59 | 72.14 | 109.98 | 77.66 | 31.76 |
| — | +27.9% | -79.8% | -2.6% | +4.1% | -42.0% | -13.6% | -75.4% | -34.0% | -69.1% | +0.4% | +96.5% | -45.5% | -31.5% | -19.7% | -50.1% | +30.9% | +114.5% | +178.6% | +145.4% | +27.0% | |
| EV / EBITDA | 9.41 | 9.94 | 10.44 | 12.27 | 11.96 | 9.10 | 13.54 | 15.12 | 22.00 | 21.27 | 20.98 | 29.37 | 22.95 | 39.46 | 17.07 | 18.69 | 26.24 | 19.11 | 16.60 | 29.43 | 52.31 |
| — | +9.2% | -22.9% | -18.8% | -45.7% | -57.2% | -35.5% | -48.5% | -4.1% | -46.1% | +22.9% | +57.1% | -12.6% | +106.5% | +2.8% | -36.5% | -49.8% | -29.9% | -44.3% | +37.7% | +147.6% | |
| EV / EBIT | 19.12 | 13.44 | 13.86 | 18.24 | 16.62 | 13.02 | 16.18 | 25.14 | 36.69 | 49.95 | 37.83 | 62.86 | 71.87 | 30.46 | 20.79 | 24.11 | 30.11 | 25.01 | 21.09 | 38.23 | 70.24 |
| — | +3.2% | -14.3% | -27.5% | -54.7% | -73.9% | -57.2% | -60.0% | -49.0% | +63.9% | +81.9% | +160.7% | +138.7% | +21.8% | -1.4% | -36.9% | -57.1% | -28.9% | -35.0% | +36.5% | +166.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.4% | 69.5% | 69.4% | 69.2% | 72.0% | 63.3% | 66.6% | 67.3% | 59.9% | 56.8% | 58.7% | 60.2% | 56.9% | 64.7% | 73.8% | 74.4% | 74.3% | 74.2% | 74.0% | 74.3% | 75.3% |
| — | +9.8% | +4.2% | +2.8% | +20.2% | +11.5% | +13.5% | +11.9% | +5.2% | -12.3% | -20.4% | -19.1% | -23.3% | -12.8% | -0.3% | +0.1% | -1.3% | -0.4% | -0.7% | -1.9% | +1.8% | |
| Operating Margin | 16.3% | 23.2% | 23.1% | 21.5% | 20.8% | 17.6% | 10.2% | 16.2% | 9.2% | 7.7% | 7.9% | 1.3% | 1.6% | 0.1% | 22.7% | 20.4% | 19.7% | 23.5% | 25.7% | 20.1% | 7.3% |
| — | +32.4% | +126.3% | +32.7% | +126.5% | +128.4% | +29.6% | +1130.3% | +458.5% | +7200.1% | -65.3% | -93.5% | -91.7% | -99.6% | -11.7% | +1.2% | +170.4% | +1.2% | +40.7% | -16.0% | -71.0% | |
| Net Margin | 18.3% | 18.5% | 19.2% | 16.4% | 17.0% | 15.5% | 27.2% | 12.6% | 4.0% | 8.3% | 5.0% | -1.2% | 2.4% | 0.3% | 19.8% | 17.8% | 18.2% | 18.7% | 20.7% | 16.5% | 6.0% |
| — | +19.5% | -29.5% | +29.7% | +322.0% | +86.7% | +439.6% | +1175.5% | +65.4% | +3085.1% | -74.5% | -106.6% | -86.6% | -98.6% | -4.4% | +7.5% | +201.9% | -9.2% | +25.1% | -17.2% | -73.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.3% | 3.0% | 3.2% | 2.7% | 3.1% | 2.7% | 4.8% | 1.8% | 0.6% | 1.3% | 0.8% | -0.2% | 0.4% | 0.0% | 3.0% | 2.6% | 2.8% | 2.7% | 3.1% | 2.2% | 0.9% |
| — | +7.9% | -34.1% | +46.3% | +387.7% | +112.4% | +501.7% | +1116.1% | +75.0% | +3889.2% | -72.8% | -106.9% | -86.8% | -98.8% | -5.5% | +21.0% | +217.6% | -2.6% | +20.8% | -26.9% | -75.9% | |
| ROA | 10.2% | 2.6% | 2.8% | 2.3% | 2.7% | 2.4% | 4.2% | 1.5% | 0.5% | 1.0% | 0.6% | -0.1% | 0.3% | 0.0% | 2.6% | 2.3% | 2.5% | 2.4% | 2.8% | 1.9% | 0.8% |
| — | +8.3% | -33.9% | +52.8% | +427.5% | +130.0% | +556.2% | +1167.6% | +78.1% | +3795.8% | -75.8% | -106.1% | -88.3% | -98.9% | -5.2% | +20.8% | +216.3% | -3.4% | +19.8% | -27.4% | -76.2% | |
| ROIC | 8.9% | 3.0% | 3.2% | 2.9% | 3.1% | 2.4% | 1.4% | 1.9% | 1.1% | 0.9% | 0.9% | 0.1% | 0.2% | 0.0% | 2.9% | 2.5% | 2.4% | 2.8% | 3.3% | 2.2% | 0.9% |
| — | +24.1% | +118.9% | +52.6% | +171.1% | +172.0% | +58.9% | +1191.4% | +538.4% | +8923.2% | -69.1% | -94.1% | -92.6% | -99.6% | -10.2% | +10.9% | +158.8% | -3.9% | +30.8% | -27.4% | -74.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.12 | — | — | 0.00 | — | — | — | — |
| — | -17.3% | -17.3% | +7.8% | -79.8% | -79.3% | -78.8% | -83.1% | -1.2% | +5.2% | — | — | +3897.8% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 0.16 | 0.43 | 0.44 | 0.49 | 0.49 | 0.58 | 0.83 | 0.57 | 4.18 | 4.65 | 4.68 | 8.31 | 6.40 | 13.84 | — | — | 0.08 | — | — | — | — |
| — | -25.1% | -46.5% | -12.8% | -88.3% | -87.5% | -82.3% | -93.2% | -34.7% | -66.4% | — | — | +7455.5% | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.26 | 4.30 | 4.62 | 4.56 | 4.26 | 4.13 | 4.07 | 4.45 | 2.54 | 2.51 | 2.42 | 2.33 | 4.88 | 4.47 | 7.80 | 6.39 | 6.18 | 6.33 | 6.10 | 6.48 | 6.17 |
| — | +4.0% | +13.5% | +2.5% | +67.6% | +64.3% | +68.1% | +91.2% | -47.9% | -43.8% | -68.9% | -63.6% | -21.0% | -29.4% | +27.7% | -1.4% | +0.1% | -20.9% | -11.0% | -1.6% | -9.3% | |
| Quick Ratio | 2.74 | 2.67 | 2.93 | 2.95 | 2.74 | 2.47 | 2.26 | 2.72 | 1.77 | 1.64 | 1.45 | 1.29 | 2.72 | 2.36 | 5.63 | 4.47 | 4.30 | 4.39 | 4.28 | 4.68 | 4.48 |
| — | +8.0% | +29.9% | +8.6% | +54.5% | +51.2% | +55.3% | +111.3% | -34.8% | -30.7% | -74.2% | -71.2% | -36.7% | -46.2% | +31.6% | -4.5% | -4.0% | -27.9% | -15.7% | -0.5% | -8.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | 94.55 | 63.22 | 26.89 | 15.61 | 10.06 | — | 8.34 | 8.89 | 11.63 | 15.14 | 26.93 | 19.15 | 13.45 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GMED stock.
Globus Medical, Inc.'s current P/E is 17.3x. The average P/E over the last 4 quarters is 20.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Globus Medical, Inc.'s current operating margin is 16.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Globus Medical, Inc.'s business trajectory between earnings reports.